Vosoritide

Overview

Vosoritide is a synthetic 39-amino-acid analog of C-type natriuretic peptide (CNP) developed by BioMarin Pharmaceutical and marketed as Voxzogo. It received FDA approval in November 2021 for the treatment of achondroplasia in pediatric patients aged 5 years and older with open epiphyses (growth plates), making it the first pharmacotherapy approved for this condition.

Achondroplasia is the most common form of disproportionate short stature, affecting approximately 1 in 15,000-40,000 live births worldwide. It is caused by gain-of-function mutations in the fibroblast growth factor receptor 3 (FGFR3) gene, with over 97% of cases involving the same G380R point mutation. Constitutive FGFR3 activation in growth plate chondrocytes suppresses chondrocyte proliferation and hypertrophy, inhibiting endochondral ossification and resulting in shortened long bones, particularly in the proximal limbs.

CNP is an endogenous 22-amino-acid peptide that acts as a local paracrine regulator of bone growth. It signals through natriuretic peptide receptor B (NPR-B), activating intracellular cyclic GMP (cGMP) production, which antagonizes the FGFR3/MAPK signaling cascade that suppresses chondrocyte differentiation. Vosoritide was engineered with enhanced stability compared to native CNP while preserving NPR-B binding and growth plate activity.

Structure and Pharmacology

Molecular characteristics:

• Structure: 39-amino-acid peptide consisting of a 17-residue N-terminal extension derived from the pro-CNP propeptide fused to the mature 22-amino-acid CNP sequence
• Molecular weight: Approximately 4,113 Da
• Key features: N-terminal extension confers resistance to neutral endopeptidase (NEP) degradation; C-terminal CNP ring structure with intramolecular Disulfide bond retained for NPR-B binding
• Administration: Subcutaneous injection, once daily

Mechanism of Action

Vosoritide's therapeutic mechanism operates at the growth plate:

1. NPR-B binding: Vosoritide binds NPR-B (also called GC-B) on growth plate chondrocytes, the same receptor targeted by endogenous CNP
2. cGMP generation: NPR-B is a transmembrane guanylate cyclase; ligand binding activates its intracellular catalytic domain, converting GTP to cGMP
3. MAPK pathway inhibition: cGMP activates cGMP-dependent protein kinase II (cGKII), which phosphorylates and inhibits RAF-1, a key kinase in the FGFR3-RAS-MAPK signaling cascade
4. FGFR3 signal antagonism: By inhibiting the MAPK pathway downstream of FGFR3, vosoritide counteracts the constitutive growth-suppressive signal that characterizes achondroplasia
5. Chondrocyte rescue: Released from FGFR3-mediated inhibition, growth plate chondrocytes resume more normal patterns of proliferation, hypertrophic differentiation, and extracellular matrix production
6. Bone elongation: Restored endochondral ossification increases the rate of linear bone growth

This mechanism is specific to actively growing bones with open epiphyses, which is why vosoritide is indicated only for pediatric patients who have not yet reached skeletal maturity.

Clinical Applications

Achondroplasia

In the Phase III trial (Study 111-301), children aged 5-18 years with achondroplasia who received vosoritide 15 mcg/kg daily subcutaneously demonstrated an increased annualized growth velocity compared to placebo over 52 weeks. Treated patients gained additional height compared to untreated natural history controls.

Long-term extension data through multiple years of treatment demonstrated sustained improvements in annualized growth velocity without evidence of tachyphylaxis. Improvements in body proportionality (upper-to-lower segment ratio) were also observed, suggesting that vosoritide partially corrects the disproportionate growth pattern characteristic of achondroplasia.

Dosing:

• 15 mcg/kg subcutaneously once daily
• Administered by a caregiver or healthcare professional
• Treatment continues as long as growth plates remain open
• Blood pressure monitoring before and after injection during treatment initiation

Investigated Applications

• Younger children with achondroplasia: Phase II trials in children aged 0-5 years
• Hypochondroplasia: A milder FGFR3-related skeletal dysplasia
• Other FGFR3-related skeletal conditions: Thanatophoric dysplasia, SADDAN syndrome (in preclinical investigation)

Pharmacokinetics

The very short half-life is notable. Despite rapid systemic clearance, the daily administration produces a transient pulse of NPR-B activation at the growth plate that is sufficient to inhibit FGFR3 signaling and promote chondrocyte activity. This pulsatile exposure may actually be advantageous, as continuous CNP-NPR-B activation could lead to receptor desensitization.

Safety Profile

• Injection site reactions: Erythema, swelling, and pain at the injection site (35-75%); generally mild
• Blood pressure decrease: Transient hypotension due to NPR-B-mediated vasodilation; blood pressure monitoring for 45 minutes after the first injection is recommended; NPR-B is also expressed on vascular smooth muscle cells, and CNP-mediated cGMP production causes vasodilation
• Nausea and vomiting: 20-28%, often transient and associated with initial dosing
• Injection site hematoma: 10-15%

No serious safety signals such as advanced bone maturation, premature growth plate closure, or disproportionate growth of non-skeletal tissues have been observed. Monitoring of growth plate status via radiographic assessment of bone age is recommended periodically during treatment.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Vosoritide (Voxzogo) is an FDA-approved treatment for achondroplasia. Always consult a qualified healthcare professional.

Administration notes: Administered by a caregiver or healthcare professional. Inject in the abdomen, thigh, or upper arm, rotating injection sites. Monitor blood pressure before and after injection during treatment initiation (transient hypotension may occur). Continue treatment as long as growth plates remain open. Periodic radiographic assessment of bone age is recommended. Ensure adequate hydration before each injection.

Scientific Context

Vosoritide exemplifies the application of natriuretic peptide biology to a non-cardiovascular indication. While the natriuretic peptide family (ANP, BNP, CNP) is primarily associated with cardiovascular regulation, CNP's role as a local growth plate modulator demonstrates the tissue-specific functions these peptides can serve. The compound also illustrates the principle of pathway-level pharmacological antagonism: rather than targeting the mutant FGFR3 receptor directly, vosoritide counteracts its downstream signaling through a parallel inhibitory pathway.

The development of vosoritide has transformed the treatment landscape for achondroplasia from a condition managed solely through orthopedic surgery and adaptive measures to one with a targeted pharmacological intervention that addresses the underlying pathophysiology during the critical growth period.